As of June 19, 2022, a cumulative total of 1,297 reports have been received, following 2,508,534 doses of COVID-19 vaccines administered, with a reporting rate of 0.52 per 1,000 doses administered (0.052% of all doses administered). Refer to Tables 1 and 2 for more details.
Table 1: Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan, as of June 19, 2022
|Pfizer 12+||Moderna||AstraZeneca||COVISHIELD||Janssen||Pfizer 5-11||Novavax||All combined|
|Total number of doses administered||1,786,550||518,251||74,923||17,023||1,869||109,610||308||2,508,534|
|Total number of AEFI reports received||832||312||113||25||3||11||1||1,297|
|Number of non-serious reports||771||300||95||24||2||10||1||1,203|
|Number of serious reports1||61||12||18||1||1||1||0||94|
|Proportion of serious AEFI reports||7%||4%||16%||4%||33%||9%||0%||7%|
|AEFI reporting rate per 1,000 doses administered||0.47||0.6||1.51||1.47||1.61||0.1||3.4||0.52|
|Serious AEFI reporting rate per 1,000 doses administered||0.03||0.02||0.24||0.06||0.54||0.01||0||0.04|
Table 2: Cumulative Frequency of AEFIs Reported
|Adverse event type||# of events|
|Edema (allergic, not injection site)||208|
|Injection site reactions||197|
There are safety signals identified by the Public Health Agency of Canada (PHAC) for vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), myocarditis/pericarditis, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) requiring provinces and territories to report these events as adverse events of special interest to the PHAC. As of June 19, 2022, 3 VITT/TTS, 33 myocarditis/pericarditis, 0 GBS and 0 CLS cases have been reported in Saskatchewan.
Information on reported adverse events following COVID-19 vaccination in Canada can be found at the PHAC AEFI reporting site at COVID-19 vaccine safety: Weekly report on side effects following immunization on Canada.ca.